FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
It's the experiences we bring to life, rather than the things we create, that build value, gain trust, and earn loyalty.
Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
Only 2.6% of board members in Standard & Poor's 1,500 firms have marketing experience.
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Midway through Campaign's audience with Publicis Groupe's Maurice Lévy, a heavily French-accented voice exclaims, "Now it is time for the real boss to arrive."
The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.
Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.
The Paris-based pharma company debuted a brand campaign and signature last week.
J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing
The association said it is preparing for new FDA approvals for therapies that treat central nervous system and muscular system diseases.
The communications team, led by Jeff Winton, is again researching Astellas' reputation for an updated picture on where the campaign has gotten them so far.
The successes of these pharma execs show that there's no one path to professional bliss.
Management turnover has brought the opportunity to keep up the pressure.
They are tasked with addressing an increasingly tough payer environment and ongoing criticism of the industry's drug-pricing practices.
What is second nature to most marketers may not be well understood by healthcare professionals who have spent their careers as physicians, researchers, or caregivers.
Novartis CEO Joe Jimenez to step down; Sanofi ends R&D plans for Zika vaccine; oncologists still struggle to predict metastasis
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Business analysts have generally agreed that WPP's half-year earnings fell below expectations given recent market commentary, but have offered mixed guidance going forward.
She will also continue to serve as president of the Astellas U.S.A. Foundation.
Former Edelman executive Mary Corcoran replaces Annalise Coady, who becomes president of W2O EMEA.
Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement
FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug
David Musselman and Lynn Gerber are now leading sales for the company's primary care and specialty products.
Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review
Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy
AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge
The CEOs of the industry's largest holding companies discuss how they're reasserting their businesses.
Discover how M&A activity in 2016 and 2017 has reshaped North American healthcare agencies and the holding companies that own them.